Have a feature idea you'd love to see implemented?
Let us know!
SLNO Soleno Therapeutics Inc
Price (delayed)
$51.08
Market cap
$1.99B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.82
Enterprise value
$1.93B
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet
Highlights
Soleno Therapeutics's quick ratio has surged by 162% QoQ
SLNO's equity has surged by 96% since the previous quarter
Soleno Therapeutics's net income has plunged by 130% YoY and by 26% from the previous quarter
Key stats
What are the main financial stats of SLNO
Market
Valuations
Earnings
Shares outstanding
38.87M
Market cap
$1.99B
Enterprise value
$1.93B
Price to earnings (P/E)
N/A
Price to book (P/B)
6.08
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$65.41M
EBITDA
-$63.17M
Free cash flow
-$42.84M
Per share
Balance sheet
Liquidity
EPS
-$1.82
Free cash flow per share
-$1.11
Book value per share
$8.4
Revenue per share
$0
TBVPS
$7.67
Total assets
$304.13M
Total liabilities
$23.37M
Debt
$296,000
Equity
$280.76M
Working capital
$258.35M
Debt to equity
0
Current ratio
29.24
Quick ratio
29.08
Net debt/EBITDA
0.9
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-36.5%
Return on equity
-43.3%
Return on invested capital
-87.3%
Return on capital employed
-22.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SLNO stock price
How has the Soleno Therapeutics stock price performed over time
Intraday
-1.71%
1 week
2.82%
1 month
4.78%
1 year
98.37%
YTD
26.91%
QTD
1.17%
Financial performance
How have Soleno Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$68.5M
Net income
-$65.41M
Gross margin
N/A
Net margin
N/A
The operating income has plunged by 138% YoY and by 28% from the previous quarter
Soleno Therapeutics's net income has plunged by 130% YoY and by 26% from the previous quarter
Growth
What is Soleno Therapeutics's growth rate over time
Valuation
What is Soleno Therapeutics stock price valuation
P/E
N/A
P/B
6.08
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 37% year-on-year and by 12% since the previous quarter
SLNO's equity has surged by 96% since the previous quarter
The price to book (P/B) is 31% lower than the last 4 quarters average of 8.8 but 29% higher than the 5-year quarterly average of 4.7
Efficiency
How efficient is Soleno Therapeutics business performance
The ROE has soared by 85% YoY and by 30% from the previous quarter
The return on invested capital has surged by 74% since the previous quarter
The company's return on assets has surged by 65% YoY and by 22% QoQ
Dividends
What is SLNO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SLNO.
Financial health
How did Soleno Therapeutics financials performed over time
Soleno Therapeutics's quick ratio has surged by 162% QoQ
SLNO's current ratio has soared by 160% QoQ
SLNO's debt is 100% smaller than its equity
The company's debt to equity has shrunk by 100% YoY
SLNO's equity has surged by 96% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.